Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Stock Competitors & Peer Comparison
See SCNI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SCNI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SCNI | $1.17 | -0.85% | 589.3K | -0.08 | -$14.23 | N/A |
| VRTX | $488.85 | -4.16% | 128.7B | 26.64 | $19.03 | N/A |
| MRNA | $216.66 | -3.71% | 84.8B | -26.23 | -$8.15 | N/A |
| REGN | $754.91 | +1.12% | 78.6B | 16.72 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $800.16 | -3.01% | 50.5B | 29.29 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $188.66 | -0.58% | 41.2B | -21.99 | -$8.82 | N/A |
| RVMDW | $9.46 | -3.12% | 39.6B | -1.14 | -$8.82 | N/A |
| ONC | $350.72 | -1.06% | 37.4B | 61.69 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SCNI vs VRTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, VRTX has a market cap of 128.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while VRTX trades at $488.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas VRTX's P/E ratio is 26.64. In terms of profitability, SCNI's ROE is -0.27%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SCNI is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
SCNI vs MRNA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MRNA has a market cap of 84.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MRNA trades at $216.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MRNA's P/E ratio is -26.23. In terms of profitability, SCNI's ROE is -0.27%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SCNI is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SCNI vs REGN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while REGN trades at $754.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas REGN's P/E ratio is 16.72. In terms of profitability, SCNI's ROE is -0.27%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SCNI is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
SCNI vs VRNA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SCNI's ROE is -0.27%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, SCNI is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
SCNI vs ARGX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ARGX has a market cap of 50.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ARGX trades at $800.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ARGX's P/E ratio is 29.29. In terms of profitability, SCNI's ROE is -0.27%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, SCNI is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
SCNI vs SGEN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SCNI's ROE is -0.27%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SCNI is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SCNI vs RVMD Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RVMD trades at $188.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RVMD's P/E ratio is -21.99. In terms of profitability, SCNI's ROE is -0.27%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, SCNI is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SCNI vs RVMDW Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RVMDW has a market cap of 39.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RVMDW trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RVMDW's P/E ratio is -1.14. In terms of profitability, SCNI's ROE is -0.27%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, SCNI is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for SCNI.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
SCNI vs ONC Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ONC has a market cap of 37.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ONC trades at $350.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ONC's P/E ratio is 61.69. In terms of profitability, SCNI's ROE is -0.27%, compared to ONC's ROE of +0.14%. Regarding short-term risk, SCNI is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SCNI vs ALNY Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ALNY has a market cap of 30.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ALNY trades at $222.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ALNY's P/E ratio is 40.90. In terms of profitability, SCNI's ROE is -0.27%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SCNI is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SCNI vs ROIV Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ROIV has a market cap of 25B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ROIV trades at $33.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ROIV's P/E ratio is -32.91. In terms of profitability, SCNI's ROE is -0.27%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, SCNI is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
SCNI vs BNTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BNTX trades at $89.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BNTX's P/E ratio is -12.43. In terms of profitability, SCNI's ROE is -0.27%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, SCNI is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SCNI vs UTHR Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, UTHR has a market cap of 23.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while UTHR trades at $547.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas UTHR's P/E ratio is 19.68. In terms of profitability, SCNI's ROE is -0.27%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, SCNI is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
SCNI vs GMAB Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, GMAB has a market cap of 22.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while GMAB trades at $36.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas GMAB's P/E ratio is 28.16. In terms of profitability, SCNI's ROE is -0.27%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SCNI is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check GMAB's competition here
Incyte Corporation (NASDAQ: INCY)
SCNI vs INCY Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, INCY has a market cap of 22.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while INCY trades at $108.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas INCY's P/E ratio is 14.97. In terms of profitability, SCNI's ROE is -0.27%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SCNI is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
SCNI vs INSM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while INSM trades at $96.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas INSM's P/E ratio is -23.98. In terms of profitability, SCNI's ROE is -0.27%, compared to INSM's ROE of -1.11%. Regarding short-term risk, SCNI is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SCNI vs BGNE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SCNI's ROE is -0.27%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, SCNI is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SCNI vs DNA-WT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SCNI's ROE is -0.27%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, SCNI is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SCNI vs EXEL Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, EXEL has a market cap of 15B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while EXEL trades at $59.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas EXEL's P/E ratio is 17.09. In terms of profitability, SCNI's ROE is -0.27%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, SCNI is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SCNI vs NBIX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, NBIX has a market cap of 14.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while NBIX trades at $135.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas NBIX's P/E ratio is 20.43. In terms of profitability, SCNI's ROE is -0.27%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SCNI is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SCNI vs ASND Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ASND has a market cap of 14.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ASND trades at $223.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ASND's P/E ratio is -93.80. In terms of profitability, SCNI's ROE is -0.27%, compared to ASND's ROE of +1.90%. Regarding short-term risk, SCNI is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
SCNI vs SMMT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, SMMT has a market cap of 13.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while SMMT trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas SMMT's P/E ratio is -15.29. In terms of profitability, SCNI's ROE is -0.27%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SCNI is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check SMMT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SCNI vs JAZZ Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, JAZZ has a market cap of 13.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while JAZZ trades at $210.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas JAZZ's P/E ratio is 8.08. In terms of profitability, SCNI's ROE is -0.27%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, SCNI is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check JAZZ's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SCNI vs HALO Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while HALO trades at $109.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas HALO's P/E ratio is 20.72. In terms of profitability, SCNI's ROE is -0.27%, compared to HALO's ROE of +1.81%. Regarding short-term risk, SCNI is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SCNI vs BBIO Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BBIO has a market cap of 12.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BBIO trades at $63.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BBIO's P/E ratio is -17.58. In terms of profitability, SCNI's ROE is -0.27%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, SCNI is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SCNI vs KRTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SCNI's ROE is -0.27%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SCNI is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SCNI vs TECH Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TECH trades at $72.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TECH's P/E ratio is 37.40. In terms of profitability, SCNI's ROE is -0.27%, compared to TECH's ROE of +0.09%. Regarding short-term risk, SCNI is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SCNI vs RNAM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SCNI's ROE is -0.27%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, SCNI is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RNAM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SCNI vs MDGL Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MDGL trades at $450.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MDGL's P/E ratio is -36.50. In terms of profitability, SCNI's ROE is -0.27%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SCNI is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SCNI vs BMRN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BMRN has a market cap of 10.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BMRN trades at $54.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BMRN's P/E ratio is 26.63. In terms of profitability, SCNI's ROE is -0.27%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, SCNI is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SCNI vs IBRX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IBRX has a market cap of 10.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IBRX trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IBRX's P/E ratio is -10.43. In terms of profitability, SCNI's ROE is -0.27%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, SCNI is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IBRX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SCNI vs PCVX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, PCVX has a market cap of 10.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while PCVX trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas PCVX's P/E ratio is -9.26. In terms of profitability, SCNI's ROE is -0.27%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, SCNI is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check PCVX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SCNI vs KRYS Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while KRYS trades at $323.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas KRYS's P/E ratio is 41.61. In terms of profitability, SCNI's ROE is -0.27%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SCNI is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SCNI vs RXDX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SCNI's ROE is -0.27%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SCNI is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RXDX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
SCNI vs TXG Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TXG has a market cap of 9.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TXG trades at $71.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TXG's P/E ratio is -127.44. In terms of profitability, SCNI's ROE is -0.27%, compared to TXG's ROE of -0.09%. Regarding short-term risk, SCNI is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TXG's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
SCNI vs TWST Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TWST has a market cap of 9.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TWST trades at $150.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TWST's P/E ratio is -68.41. In terms of profitability, SCNI's ROE is -0.27%, compared to TWST's ROE of -0.30%. Regarding short-term risk, SCNI is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TWST's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SCNI vs PTGX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while PTGX trades at $138.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas PTGX's P/E ratio is 140.66. In terms of profitability, SCNI's ROE is -0.27%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, SCNI is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SCNI vs KYMR Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while KYMR trades at $107.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas KYMR's P/E ratio is -35.02. In terms of profitability, SCNI's ROE is -0.27%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, SCNI is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check KYMR's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SCNI vs NUVL Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SCNI's ROE is -0.27%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SCNI is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SCNI vs CRNX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CRNX's P/E ratio is -16.86. In terms of profitability, SCNI's ROE is -0.27%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SCNI is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SCNI vs IMGN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SCNI's ROE is -0.27%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SCNI is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SCNI vs ARWR Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ARWR has a market cap of 8.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ARWR trades at $58.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ARWR's P/E ratio is -26.99. In terms of profitability, SCNI's ROE is -0.27%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, SCNI is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ARWR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SCNI vs AXSM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, AXSM has a market cap of 8.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while AXSM trades at $156.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas AXSM's P/E ratio is -43.34. In terms of profitability, SCNI's ROE is -0.27%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, SCNI is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check AXSM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SCNI vs TGTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TGTX has a market cap of 8.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TGTX trades at $54.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TGTX's P/E ratio is 20.03. In terms of profitability, SCNI's ROE is -0.27%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, SCNI is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TGTX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SCNI vs APGE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas APGE's P/E ratio is -31.19. In terms of profitability, SCNI's ROE is -0.27%, compared to APGE's ROE of -0.30%. Regarding short-term risk, SCNI is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check APGE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SCNI vs CAI Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CAI has a market cap of 8.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CAI trades at $29.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CAI's P/E ratio is 83.42. In terms of profitability, SCNI's ROE is -0.27%, compared to CAI's ROE of +0.19%. Regarding short-term risk, SCNI is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CAI's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SCNI vs BPMC Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SCNI's ROE is -0.27%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SCNI is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SCNI vs CERE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CERE's P/E ratio is -16.47. In terms of profitability, SCNI's ROE is -0.27%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SCNI is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SCNI vs CYTK Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CYTK trades at $62.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CYTK's P/E ratio is -8.70. In terms of profitability, SCNI's ROE is -0.27%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, SCNI is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CYTK's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
SCNI vs SYRE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, SYRE has a market cap of 7.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while SYRE trades at $82.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas SYRE's P/E ratio is -44.05. In terms of profitability, SCNI's ROE is -0.27%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, SCNI is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
SCNI vs MTSR Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SCNI's ROE is -0.27%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, SCNI is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SCNI vs IONS Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IONS has a market cap of 7.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IONS trades at $42.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IONS's P/E ratio is -13.35. In terms of profitability, SCNI's ROE is -0.27%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SCNI is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SCNI vs PRAX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, PRAX has a market cap of 7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while PRAX trades at $243.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas PRAX's P/E ratio is -19.44. In terms of profitability, SCNI's ROE is -0.27%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, SCNI is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
SCNI vs MRUS Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SCNI's ROE is -0.27%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, SCNI is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SCNI vs ACLX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SCNI's ROE is -0.27%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, SCNI is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SCNI vs RETA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RETA's P/E ratio is -66.29. In terms of profitability, SCNI's ROE is -0.27%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SCNI is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RETA's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
SCNI vs IOVA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IOVA has a market cap of 6.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IOVA trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IOVA's P/E ratio is -19.95. In terms of profitability, SCNI's ROE is -0.27%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, SCNI is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IOVA's competition here
Abivax S.A. (NASDAQ: ABVX)
SCNI vs ABVX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ABVX has a market cap of 6.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ABVX trades at $85.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ABVX's P/E ratio is -14.24. In terms of profitability, SCNI's ROE is -0.27%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, SCNI is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ABVX's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SCNI vs BLTE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while BLTE trades at $152.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas BLTE's P/E ratio is -84.81. In terms of profitability, SCNI's ROE is -0.27%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, SCNI is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check BLTE's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SCNI vs CNTA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SCNI's ROE is -0.27%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SCNI is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SCNI vs LGND Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while LGND trades at $301.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas LGND's P/E ratio is 34.15. In terms of profitability, SCNI's ROE is -0.27%, compared to LGND's ROE of +0.20%. Regarding short-term risk, SCNI is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check LGND's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
SCNI vs KOD Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while KOD trades at $91.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas KOD's P/E ratio is -23.80. In terms of profitability, SCNI's ROE is -0.27%, compared to KOD's ROE of -2.73%. Regarding short-term risk, SCNI is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check KOD's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SCNI vs RYTM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RYTM trades at $87.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RYTM's P/E ratio is -28.88. In terms of profitability, SCNI's ROE is -0.27%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, SCNI is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RYTM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SCNI vs TERN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TERN's P/E ratio is -51.41. In terms of profitability, SCNI's ROE is -0.27%, compared to TERN's ROE of -0.14%. Regarding short-term risk, SCNI is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TERN's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SCNI vs IMVT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IMVT has a market cap of 6.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IMVT trades at $28.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IMVT's P/E ratio is -10.45. In terms of profitability, SCNI's ROE is -0.27%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, SCNI is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IMVT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SCNI vs CDTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SCNI's ROE is -0.27%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, SCNI is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CDTX's competition here
CG Oncology Inc. (NASDAQ: CGON)
SCNI vs CGON Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CGON trades at $62.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CGON's P/E ratio is -23.47. In terms of profitability, SCNI's ROE is -0.27%, compared to CGON's ROE of -0.25%. Regarding short-term risk, SCNI is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CGON's competition here
Abcam plc (NASDAQ: ABCM)
SCNI vs ABCM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SCNI's ROE is -0.27%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SCNI is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SCNI vs ISEE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SCNI's ROE is -0.27%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SCNI is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
SCNI vs ERAS Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ERAS trades at $14.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ERAS's P/E ratio is -16.62. In terms of profitability, SCNI's ROE is -0.27%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, SCNI is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ERAS's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SCNI vs APLS Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas APLS's P/E ratio is 38.35. In terms of profitability, SCNI's ROE is -0.27%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SCNI is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SCNI vs PTCT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while PTCT trades at $60.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas PTCT's P/E ratio is -27.00. In terms of profitability, SCNI's ROE is -0.27%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SCNI is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check PTCT's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SCNI vs MIRM Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MIRM has a market cap of 5.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MIRM trades at $80.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MIRM's P/E ratio is -5.91. In terms of profitability, SCNI's ROE is -0.27%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, SCNI is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MIRM's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SCNI vs COGT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while COGT trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas COGT's P/E ratio is -14.26. In terms of profitability, SCNI's ROE is -0.27%, compared to COGT's ROE of -0.73%. Regarding short-term risk, SCNI is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check COGT's competition here
Veradermics, Incorporated (NYSE: MANE)
SCNI vs MANE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MANE has a market cap of 5.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MANE trades at $117.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MANE's P/E ratio is -38.94. In terms of profitability, SCNI's ROE is -0.27%, compared to MANE's ROE of -0.38%. Regarding short-term risk, SCNI is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
SCNI vs SRRK Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, SRRK has a market cap of 5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while SRRK trades at $41.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas SRRK's P/E ratio is -12.16. In terms of profitability, SCNI's ROE is -0.27%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, SCNI is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check SRRK's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SCNI vs CRSP Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CRSP trades at $50.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CRSP's P/E ratio is -10.60. In terms of profitability, SCNI's ROE is -0.27%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, SCNI is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CRSP's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SCNI vs ORKA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ORKA has a market cap of 4.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ORKA trades at $79.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ORKA's P/E ratio is -41.42. In terms of profitability, SCNI's ROE is -0.27%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, SCNI is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ORKA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SCNI vs TVTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TVTX trades at $51.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TVTX's P/E ratio is -115.60. In terms of profitability, SCNI's ROE is -0.27%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, SCNI is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TVTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SCNI vs DNTH Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while DNTH trades at $77.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas DNTH's P/E ratio is -19.66. In terms of profitability, SCNI's ROE is -0.27%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, SCNI is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SCNI vs FOLD Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SCNI's ROE is -0.27%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, SCNI is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check FOLD's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SCNI vs DFTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while DFTX trades at $34.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas DFTX's P/E ratio is N/A. In terms of profitability, SCNI's ROE is -0.27%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, SCNI is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check DFTX's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SCNI vs AKRO Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SCNI's ROE is -0.27%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, SCNI is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SCNI vs ALPN Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SCNI's ROE is -0.27%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SCNI is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ALPN's competition here
Opthea Limited (NASDAQ: OPT)
SCNI vs OPT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas OPT's P/E ratio is -1.52. In terms of profitability, SCNI's ROE is -0.27%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SCNI is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SCNI vs PRTC Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SCNI's ROE is -0.27%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SCNI is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SCNI vs EWTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while EWTX trades at $36.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas EWTX's P/E ratio is -20.78. In terms of profitability, SCNI's ROE is -0.27%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, SCNI is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SCNI vs MRTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SCNI's ROE is -0.27%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SCNI is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SCNI vs ADPT Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ADPT trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ADPT's P/E ratio is -62.37. In terms of profitability, SCNI's ROE is -0.27%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SCNI is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ADPT's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
SCNI vs RLAY Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RLAY has a market cap of 3.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RLAY trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RLAY's P/E ratio is -11.45. In terms of profitability, SCNI's ROE is -0.27%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, SCNI is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RLAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
SCNI vs TNGX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TNGX has a market cap of 3.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TNGX trades at $22.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TNGX's P/E ratio is -29.12. In terms of profitability, SCNI's ROE is -0.27%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, SCNI is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TNGX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
SCNI vs ABCL Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while ABCL trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas ABCL's P/E ratio is -23.40. In terms of profitability, SCNI's ROE is -0.27%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, SCNI is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
SCNI vs CPRX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CPRX's P/E ratio is 17.49. In terms of profitability, SCNI's ROE is -0.27%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SCNI is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CPRX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
SCNI vs TLX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while TLX trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas TLX's P/E ratio is 117.85. In terms of profitability, SCNI's ROE is -0.27%, compared to TLX's ROE of +0.07%. Regarding short-term risk, SCNI is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
SCNI vs RYZB Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SCNI's ROE is -0.27%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SCNI is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
SCNI vs CBAY Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SCNI's ROE is -0.27%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SCNI is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check CBAY's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
SCNI vs SWTX Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas SWTX's P/E ratio is -13.78. In terms of profitability, SCNI's ROE is -0.27%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, SCNI is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check SWTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SCNI vs XENE Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, XENE has a market cap of 3.5B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while XENE trades at $34.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas XENE's P/E ratio is -7.61. In terms of profitability, SCNI's ROE is -0.27%, compared to XENE's ROE of -0.44%. Regarding short-term risk, SCNI is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check XENE's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
SCNI vs IDYA Comparison October 2026
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SCNI stands at 589.3K. In comparison, IDYA has a market cap of 3.4B. Regarding current trading prices, SCNI is priced at $1.17 on the NASDAQ, while IDYA trades at $34.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SCNI currently has a P/E ratio of -0.08, whereas IDYA's P/E ratio is -18.59. In terms of profitability, SCNI's ROE is -0.27%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, SCNI is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for SCNI.Check IDYA's competition here